1995
Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. JAMA Dermatology 1995, 131: 432-5. PMID: 7726585, DOI: 10.1001/archderm.131.4.432.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinomaMalignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation
Licata A, Wilson L, Braverman I, Feldman A, Kacinski B. Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation. JAMA Dermatology 1995, 131: 432-435. DOI: 10.1001/archderm.1995.01690160060009.Peer-Reviewed Original ResearchTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma
1994
The utility of adjuvant psoralen + ultraviolet-a light [PUVA] therapy in maintaining cutaneous remission in T1 and T2 CTCL (mycosis fungoides) treated with total skin electron beam radiation therapy [TSEBT]
Kolenli S, Kacinski B, Quiros P, Wilson L, Heald P, Edelson R, Braverman I. The utility of adjuvant psoralen + ultraviolet-a light [PUVA] therapy in maintaining cutaneous remission in T1 and T2 CTCL (mycosis fungoides) treated with total skin electron beam radiation therapy [TSEBT]. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 266. DOI: 10.1016/0360-3016(94)90820-6.Peer-Reviewed Original Research
1993
Cyclosporine treatment of refractory T‐cell lymphomas
Cooper D, Braverman I, Sarris A, Durivage H, Saidman B, Davis C, Hait W. Cyclosporine treatment of refractory T‐cell lymphomas. Cancer 1993, 71: 2335-2341. PMID: 8453556, DOI: 10.1002/1097-0142(19930401)71:7<2335::aid-cncr2820710727>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaPeripheral T-cell lymphomaRefractory T-cell lymphomaT-cell lymphomaMost patientsDisease progressionReinstitution of therapySubsequent graft rejectionPhase II trialT cell expansionT-cell neoplasmsTranscription of cytokinesCyclosporine treatmentClinical remissionII trialPrevious therapyRecurrent diseaseCsA administrationGraft rejectionRenal toxicityAntiinflammatory effectsRapid recurrenceTransplanted organsInterleukin-2Radiation therapy